OR WAIT null SECS
Check out the latest features and columns!
Pharm Exec profiles its 2022 Emerging Pharma Leaders
Biopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation
June's Executive Profile features Tremeau CEO, Bradford Sippy
The windfall from COVID-19 vaccines and treatments has shaken up Pharm Exec’s latest listing of the top global biopharma sales producers in record-breaking fashion
Highlighted Videos
June 13, 2022
Doceree ABM empowers healthcare marketers to reach institutional stakeholders and measure account lift.
The new user experience improvements will make it easier for members to discover and interact with relevant products related to their medical specialty.
The former North America President and CEO of Daiichi Sankyo will lead Ascletis' corporate business development and alliance management.
While the pharmaceutical industry has historically lagged behind other industries in the overall shift to programmatic advertising, the pandemic accelerated this transformation to emerging channels like connected TV (CTV).
Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).
New accelerator will develop products and solutions with the use of digital, data, and AI.
June 09, 2022
The windfall from COVID-19 vaccines and treatments has shaken up Pharm Exec’s latest listing of the top global biopharma sales producers in record-breaking fashion, but a likely leveling off—along with challenging patent and global climates—should shift some of the spotlight to anticipated non-COVID risers and perhaps more definitive maneuvering ahead.
Outlining the implications of this c-suite trend for pharma.
Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.
A flurry of new titles entering the executive ranks has its pros and cons.
